NCT00508274 - Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2007

Primary Completion Date

December 2, 2015

Study Completion Date

July 1, 2020

Conditions

Neoplasms, Breast

Interventions

DRUG

lapatinib

Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.

DRUG

capecitabine

Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.

Trial Locations (11)

Novartis Investigative Site, Beijing

Novartis Investigative Site, Beijing

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Nanjing

Novartis Investigative Site, Hangzhou

Novartis Investigative Site, Hangzhou

Novartis Investigative Site, Wuhan

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Shatin